NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis

Vertex Pharmaceuticals Incorporated (VRTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VRTX

$546.12

−$11.84 (−2.12%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VRTX with… →

VRTX Key Statistics

As of Sep 4, 2026
Trading
Open
$549.50
Previous Close
$557.96
Day's Range
544.48–556.99
52-Week Range
374.17–560.25
Volume
803.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.32
Valuation
Market Cap
$138.42B
P/E Ratio
32.47
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
25.08
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.70
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
11.00
EPS (ttm)Profit attributable to each share over the last twelve months.
16.82
Financials (FY)
Revenue (FY)
$12.00B+8.90%
Net Income (FY)
$3.95B
Profit marginThe share of revenue left as profit after all costs and taxes.
35.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
253.46M
1-Year Return
+37.59%
Dividend and dates
Earnings Date
November 2, 2026
Avg Volume
1.48M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VRTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+20.46%
2025+12.58%
2024−1.03%
2023+40.90%
2022+31.50%
2021−7.08%
2020+7.94%
2019+32.13%
2018+10.58%
2017+103.42%
2016 (partial year)−28.11%

As of September 4, 2026.

VRTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$12.00B$3.95B32.9%
2024$11.02B−$535.60M−4.9%
2023$9.87B$3.62B36.7%
2022$8.93B$3.32B37.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$12.00B$10.35B$4.55B$3.95B32.9%
2024$11.02B$9.49B−$233.40M−$535.60M−4.9%
2023$9.87B$8.61B$3.78B$3.62B36.7%
2022$8.93B$7.85B$4.25B$3.32B37.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VRTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricVRTXBiotechnology medianvs median
P/E32.4712.57158% above
P/S ratio11.0015.2628% below
Profit margin35.00%0.00%35.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Vertex Pharmaceuticals Incorporated (VRTX) is capitalised at $138.42B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 6,400.

VRTX last closed at $546.12 on September 4, 2026. That is −$11.84 (−2.12%) against the previous close. Over the past 52 weeks the price has ranged from $374.17 to $560.25. The latest close sits 45.96% above that 52-week low.

Financial Health

In fiscal 2025, Vertex Pharmaceuticals Incorporated reported revenue of $12.00B. That is +8.90% against the prior fiscal year, when revenue was $11.02B. Net income for the same year was $3.95B. Profit margin runs at 35%. That is 35 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 16.82.

Across the 4 fiscal years on file, revenue moves from $8.93B in 2022 to $12.00B in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 32.47 times earnings. That is 158.31% above the Biotechnology median of 12.57. The forward P/E on file is 25.08. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.7. The price-to-sales ratio is 11. On price-to-sales that is 27.95% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.32. Annualized volatility over the trailing 10 years is 32.78%. Over the trailing twelve months the price has returned +37.59%. Measured over 10 years, that is +19.10% a year compounded.

Growth & Income

The record shows no dividend for VRTX.

Across the complete calendar years on file, 2017 returned +103.42% and 2021 returned −7.08%. Of the 9 complete calendar years on file, 7 finished higher. 2026 is still running; the price is +20.46% year to date.

Peer Comparison

Vertex Pharmaceuticals Incorporated (VRTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1
Moderna, Inc. MRNA $58.11B —

The Biotechnology industry average P/E ratio is 12.6x. Vertex Pharmaceuticals Incorporated trades at a P/E of 32.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B

 RPRX

Royalty Pharma plc

$36.96B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Visit website →